Fulvio Basolo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7974484/publications.pdf

Version: 2024-02-01

363 papers	20,878 citations	10351 72 h-index	14156 128 g-index
366 all docs	366 docs citations	366 times ranked	15280 citing authors

#	Article	IF	Citations
1	NanoString in the screening of genetic abnormalities associated with thyroid cancer. Seminars in Cancer Biology, 2022, 79, 132-140.	4.3	4
2	COVID-19 autopsy cases: detection of virus in endocrine tissues. Journal of Endocrinological Investigation, 2022, 45, 209-214.	1.8	58
3	Histological pattern and gene expression profiling of thyroid tissue in subjects with obesity. Journal of Endocrinological Investigation, 2022, 45, 413-423.	1.8	10
4	Role of the mononuclear cell infiltrate in Gravesâ€™ orbitopathy (GO): results of a large cohort study. Journal of Endocrinological Investigation, 2022, 45, 563-572.	1.8	9
5	Sarcina Ventriculi infection: a rare but fearsome event. A Systematic Review of the Literature. International Journal of Infectious Diseases, 2022, 115, 48-61.	1.5	17
6	Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center. Cancers, 2022, 14, 420.	1.7	5
7	Response to Letter to the Editor From Green and Gosmanov: â€œTall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patientsâ€™ Clinical Managementâ€. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	0
8	Adipose tissue in COVID-19: detection of SARS-CoV-2 in adipocytes and activation of the interferon-alpha response. Journal of Endocrinological Investigation, 2022, 45, 1021-1029.	1.8	33
9	Down-regulation of miR-7-5p and miR-548ar-5p predicts malignancy in indeterminate thyroid nodules negative for BRAF and RAS mutations. Endocrine, 2022, 76, 677-686.	1.1	3
10	Salvage total thyroidectomy for amiodarone-induced thyrotoxicosis in a SARS-CoV-2 positive patient: results of the viral genome research on the pathology sample of this destructive thyroiditis. Endocrine, 2022, 76, 495-498.	1.1	2
11	Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses. Frontiers in Oncology, 2022, 12, 854755.	1.3	12
12	Bilateral testicular metastases of medullary thyroid carcinoma in an adult male with multiple endocrine neoplasia 2A syndrome: case report and review of literature. European Thyroid Journal, 2022, 11, .	1.2	1
13	Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3420-e3427.	1.8	8
14	Intestinal Ischemia: Unusual but Fearsome Complication of COVID-19 Infection. Biomedicines, 2022, 10, 1010.	1.4	2
15	Predictive Biomarkers in Thyroid Cancer. Frontiers in Oncology, 2022, 12, .	1.3	5
16	Suppression of Pituitary Hormone Genes in Subjects Who Died From COVID-19 Independently of Virus Detection in the Gland. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2243-2253.	1.8	9
17	Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma. International Journal of Molecular Sciences, 2022, 23, 7470.	1.8	5
18	The <scp>I</scp>talian <scp>C</scp>onsensus for the <scp>C</scp>lassification and <scp>R</scp>eporting of <scp>T</scp>hyroid <scp>C</scp>ytology: Cytohistologic and molecular correlations on 37,371 nodules from a single institution. Cancer Cytopathology, 2022, 130, 899-912.	1.4	7

#	Article	IF	Citations
19	Developing a tool that could reliably refute total thyroidectomy for solitary Bethesda IV thyroid nodules. Updates in Surgery, 2021, 73, 281-288.	0.9	1
20	Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma. Endocrine, 2021, 72, 140-146.	1.1	2
21	Genetic Profiling of Orbital Fibroblasts from Patients with Gravesâ€™ Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2176-e2190.	1.8	18
22	RET mutated C-cells proliferate more rapidly than non-mutated neoplastic cells. Endocrine Connections, 2021, 10, 124-130.	0.8	3
23	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Endocrine-Related Cancer, 2021, 28, 111-134.	1.6	14
24	Molecular Genetics of Follicular-Derived Thyroid Cancer. Cancers, 2021, 13, 1139.	1.7	29
25	Tall cell percentage alone in PTC without aggressive features should not guide patientsâ€™ clinical management. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4109-e4117.	1.8	13
26	Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4072-e4083.	1.8	10
27	Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. Cancers, 2021, 13, 3123.	1.7	14
28	Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4565-e4579.	1.8	7
29	Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests. Thyroid, 2021, 31, 1463-1471.	2.4	4
30	Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19. Thyroid, 2021, 31, 1766-1775.	2.4	24
31	A pandemic recap: lessons we have learned. World Journal of Emergency Surgery, 2021, 16, 46.	2.1	16
32	Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma. Cancers, 2021, 13, 94.	1.7	14
33	Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma. Biomolecules, 2021, 11, 1542.	1.8	5
34	RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency. Genes, 2021, 12, 35.	1.0	2
35	Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia. Cancers, 2021, 13, 5554.	1.7	5
36	Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer. Endocrine Practice, 2020, 26, 58-71.	1.1	14

#	Article	IF	Citations
37	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e172-e180.	1.8	94
38	Digital Gene Expression Analysis on CytologyÂSmears Can Rule Out Malignancy inÂFollicular-Patterned Thyroid Tumors. Journal of Molecular Diagnostics, 2020, 22, 179-187.	1.2	9
39	Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1124-e1134.	1.8	21
40	Immune Transcriptome of Cells Infected with Enterovirus Strains Obtained from Cases of Type 1 Diabetes. Microorganisms, 2020, 8, 1031.	1.6	13
41	A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion. Case Reports in Endocrinology, 2020, 2020, 1-7.	0.2	3
42	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2845-e2852.	1.8	7
43	Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up. Endocrine, 2020, 68, 607-616.	1.1	11
44	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. In Vivo, 2020, 34, 2061-2066.	0.6	3
45	Exploring the Inter-observer Agreement Among the Members of the Italian Consensus for the Classification and Reporting of Thyroid Cytology. Endocrine Pathology, 2020, 31, 301-306.	5.2	8
46	Noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP): a new entity. Gland Surgery, 2020, 9, S47-S53.	0.5	9
47	Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. Endocrine Practice, 2020, 26, 807-817.	1.1	15
48	MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis?. Journal of the Endocrine Society, 2020, 4, .	0.1	0
49	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3557-3575.	1.8	41
50	A Case of Unilateral Dermopathy Possibly Related to Gravesâ€™ Disease. European Thyroid Journal, 2019, 8, 278-282.	1.2	1
51	Sudden death in a case of recurrent Takotsubo syndrome. Forensic Science, Medicine, and Pathology, 2019, 15, 595-597.	0.6	10
52	Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. IScience, 2019, 20, 324-336.	1.9	122
53	BRAFV600E mutation: a potential predictor of more than a Sistrunkâ€™s procedure in patients with thyroglossal duct cyst carcinoma and a normal thyroid gland. Updates in Surgery, 2019, 71, 701-704.	0.9	11
54	A microRNA signature for the differential diagnosis of salivary gland tumors. PLoS ONE, 2019, 14, e0210968.	1.1	17

#	Article	IF	Citations
55	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2520-2526.	1.8	15
56	Junctional adhesion moleculeâ€A is downâ€regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 Î±/Î² pathways. Molecular Carcinogenesis, 2019, 58, 1181-1193.	1.3	19
57	miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine, 2019, 65, 582-594.	1.1	26
58	Myofibroblast Gene Expression Profile after Tooth Extraction in the Rabbit. Materials, 2019, 12, 3697.	1.3	16
59	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. Frontiers in Oncology, 2019, 9, 1390.	1.3	3
60	mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases. Molecular and Cellular Endocrinology, 2019, 479, 93-102.	1.6	7
61	The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology. Journal of Endocrinological Investigation, 2019, 42, 157-166.	1.8	19
62	Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms. Endocrine-Related Cancer, 2019, 26, 451-462.	1.6	8
63	DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions. Oncotarget, 2019, 10, 1785-1797.	0.8	20
64	TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases. Oncology Letters, 2018, 15, 2763-2770.	0.8	19
65	Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. JAMA Ophthalmology, 2018, 136, 613.	1.4	52
66	A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. Endocrine Connections, 2018, 7, 124-132.	0.8	12
67	Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. Head and Neck, 2018, 40, 1752-1758.	0.9	30
68	Current methodologies for molecular screening of thyroid nodules. Gland Surgery, 2018, 7, S1-S7.	0.5	4
69	Diagnosis of post-surgical fine-needle aspiration biopsies of thyroid lesions with indeterminate cytology using HRMAS NMR-based metabolomics. Metabolomics, 2018, 14, 141.	1.4	22
70	RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget, 2018, 9, 9875-9884.	0.8	33
71	Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surgery, 2018, 7, S19-S29.	0.5	44
72	Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. Oncology Letters, 2018, 15, 9174-9182.	0.8	25

#	Article	IF	Citations
73	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without¹³¹I Ablation. Thyroid, 2018, 28, 871-879.	2.4	35
74	Cell differentiation in cardiac myxomas: confocal microscopy and gene expression analysis after laser capture microdissection. Heart and Vessels, 2018, 33, 1403-1410.	0.5	3
75	Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature. Scientific Reports, 2018, 8, 10623.	1.6	25
76	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. Journal of Endocrinological Investigation, 2018, 41, 849-876.	1.8	165
77	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. Thyroid, 2018, 28, 1318-1324.	2.4	6
78	A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma. Oncotarget, 2018, 9, 4496-4510.	0.8	18
79	Abstract 5402: A panel of miRNAs for diagnosis of wild-type thyroid nodules with pre-surgical indeterminate cytology. , 2018, , .		0
80	Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine, 2017, 55, 386-397.	1.1	42
81	BRAF^{K601E} Mutation in a Follicular Thyroid Adenoma: A Case Report. International Journal of Surgical Pathology, 2017, 25, 348-351.	0.4	19
82	Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery, 2017, 161, 1122-1128.	1.0	26
83	Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. Cancer Letters, 2017, 411, 35-43.	3.2	25
84	Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 769-773.	1.4	11
85	Differences in miRNA expression profiles between wild-type and mutated NIFTPs. Endocrine-Related Cancer, 2017, 24, 543-553.	1.6	16
86	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature Reviews Endocrinology, 2017, 13, 644-660.	4.3	324
87	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3091-3096.	1.8	2
88	Role of YAP-1 in Thyroid Tumor Progression and Outcome. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 581-585.	0.6	7
89	The Molecular Landscape of Noninvasive Follicular Thyroid Neoplasm With Papillary-like Nuclear Features (NIFTP): A Literature Review. Advances in Anatomic Pathology, 2017, 24, 252-258.	2.4	28
90	Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. Oncology Letters, 2017, 14, 2186-2190.	0.8	3

#	Article	IF	Citations
91	Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. Thyroid, 2017, 27, 1267-1276.	2.4	28
92	Low Elasticity of Thyroid Nodules on Ultrasound Elastography Is Correlated with Malignancy, Degree of Fibrosis, and High Expression of Galectin-3 and Fibronectin-1. Thyroid, 2017, 27, 103-110.	2.4	34
93	Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. Journal of Endocrinological Investigation, 2017, 40, 55-62.	1.8	25
94	miRNA expression profiling of â€˜noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas. Modern Pathology, 2017, 30, 39-51.	2.9	65
95	MicroRNA-based molecular classification of papillary thyroid carcinoma. International Journal of Oncology, 2017, 50, 1767-1777.	1.4	67
96	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58
97	HumanÎ±-L-fucosidase-1attenuates the invasive properties of thyroid cancer. Oncotarget, 2017, 8, 27075-27092.	0.8	24
98	Intimal Sarcoma of the Descending Aorta Mimicking Aortitis. Aorta, 2016, 04, 142-145.	0.1	7
99	TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells. Oncotarget, 2016, 7, 70575-70588.	0.8	28
100	A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. Oncotarget, 2016, 7, 28510-28522.	0.8	15
101	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathology, 2016, 124, 616-620.	1.4	105
102	Role of gene expression profiling in defining indeterminate thyroid nodules in addition to <scp>BRAF</scp> analysis. Cancer Cytopathology, 2016, 124, 340-349.	1.4	17
103	New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with doubleRETmutations. Journal of Medical Genetics, 2016, 53, 729-734.	1.5	61
104	Metastasis of renal cell carcinoma to the parathyroid gland 16 years after radical nephrectomy: A case report. Oncology Letters, 2016, 12, 3224-3228.	0.8	7
105	â€˜Incidentalâ€™ and â€˜non-incidentalâ€™ thyroid papillary microcarcinomas are two different entities. European Journal of Endocrinology, 2016, 174, 813-820.	1.9	17
106	Cytological features of â€œnoninvasive follicular thyroid neoplasm with papillary-like nuclear featuresâ€•and their correlation with tumor histology. Human Pathology, 2016, 54, 134-142.	1.1	190
107	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
108	Lipomatous hamartoma-like lesion of a bicuspid aortic valve: an incidental surgical finding. Cardiovascular Pathology, 2016, 25, 500-502.	0.7	1

#	Article	IF	Citations
109	Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4413-4420.	1.8	45
110	Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate Surgery. Thyroid, 2016, 26, 390-394.	2.4	21
111	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
112	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2016, 126, 1603-1603.	3.9	111
113	Molecular genetic features and risk assessment in a series of 30 patients who underwent an operation for gastrointestinal stormal tumours. South African Journal of Surgery, 2016, 54, 23-27.	0.1	2
114	A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule. World Journal of Surgical Oncology, 2015, 13, 270.	0.8	18
115	Digital gene expression profiling of a series of cytologically indeterminate thyroid nodules. Cancer Cytopathology, 2015, 123, 461-470.	1.4	11
116	Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1316-1324.	1.8	240
117	Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. European Journal of Endocrinology, 2015, 173, 297-304.	1.9	29
118	Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 177-184.	1.4	59
119	Twenty years of lesson learning: how does the <scp>RET</scp> genetic screening test impact the clinical management of medullary thyroid cancer?. Clinical Endocrinology, 2015, 82, 892-899.	1.2	46
120	Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	2.3	126
121	The Large Majority of 1520 Patients With Indeterminate Thyroid Nodule at Cytology Have a Favorable Outcome, and a Clinical Risk Score Has a High Negative Predictive Value for a More Cumbersome Cancer Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3700-3707.	1.8	47
122	Identification of Targets of Twist1 Transcription Factor in Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1617-E1626.	1.8	23
123	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	0.8	7
124	FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment. Thyroid, 2014, 24, 339-346.	2.4	23
125	First evidence of <scp>TRPV</scp>5 and <scp>TRPV</scp>6 channels in human parathyroid glands: possible involvement in neoplastic transformation. Journal of Cellular and Molecular Medicine, 2014, 18, 1944-1952.	1.6	12
126	Molecular characterization of 54 cases of falseâ€negative fineâ€needle aspiration among 1347 papillary thyroid carcinomas. Cancer Cytopathology, 2014, 122, 751-759.	1.4	18

#	Article	IF	Citations
127	Prevalence of Thyroid Cancer in Multinodular Goiter Versus Single Nodule: Iodine Intake and Cancer Phenotypes. Thyroid, 2014, 24, 604-605.	2.4	2
128	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
129	BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy. Langenbeck's Archives of Surgery, 2014, 399, 225-228.	0.8	13
130	E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features. Surgery, 2014, 156, 1550-1558.	1.0	3
131	b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. Atherosclerosis, 2014, 237, 307-313.	0.4	24
132	Italian consensus for the classification and reporting of thyroid cytology. Journal of Endocrinological Investigation, 2014, 37, 593-599.	1.8	322
133	Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules. Current Genomics, 2014, 15, 171-177.	0.7	14
134	Incidental versus clinically evident thyroid cancer: A 5â€year followâ€up study. Head and Neck, 2013, 35, 408-412.	0.9	7
135	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1465-E1473.	1.8	33
136	Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations Occur Rarely in Sporadic Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2800-2810.	1.8	29
137	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer, 2013, 81, 377-381.	0.9	8
138	Evidence of a Low Prevalence ofRASMutations in a Large Medullary Thyroid Cancer Series. Thyroid, 2013, 23, 50-57.	2.4	151
139	Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E811-E819.	1.8	77
140	CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocrine Connections, 2013, 2, 186-195.	0.8	76
141	Medullary Thyroid Cancer Secreting Carbohydrate Antigen 19-9 (Ca 19-9): A Fatal Case Report. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3550-3554.	1.8	23
142	Presence in the Pre-Surgical Fine-Needle Aspiration of Potential Thyroid Biomarkers Previously Identified in the Post-Surgical One. PLoS ONE, 2013, 8, e72911.	1.1	18
143	Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2013, 36, 174-9.	1.8	11
144	Follicular-derived neoplasms: morphometric and genetic differences. Journal of Endocrinological Investigation, 2013, 36, 1055-61.	1.8	7

#	Article	IF	Citations
145	TheBRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4390-4398.	1.8	213
146	Thyroglobulin Autoantibodies in Patients with Papillary Thyroid Carcinoma: Comparison of Different Assays and Evaluation of Causes of Discrepancies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3974-3982.	1.8	47
147	CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Modern Pathology, 2012, 25, 46-55.	2.9	35
148	The Timing of Total Thyroidectomy inRETGene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 426-435.	1.8	119
149	Lymphocytic Thyroiditis on Histology Correlates with Serum Thyroglobulin Autoantibodies in Patients with Papillary Thyroid Carcinoma: Impact on Detection of Serum Thyroglobulin. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2380-2387.	1.8	61
150	FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, 695-710.	1.6	36
151	A case of metastatic haemangiopericytoma to the thyroid gland: Case report and literature review. Oncology Letters, 2012, 3, 1255-1258.	0.8	5
152	Toward the Reliable Diagnosis of Indeterminate Thyroid Lesions: A HRMAS NMR-Based Metabolomics Case of Study. Journal of Proteome Research, 2012, 11, 3317-3325.	1.8	45
153	Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. Molecular and Cellular Endocrinology, 2012, 348, 176-182.	1.6	19
154	Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine, 2012, 59, 218-222.	1.4	26
155	Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer. Thyroid, 2012, 22, 476-481.	2.4	60
156	Metabolomics approach to thyroid nodules: A high-resolution magic-angle spinning nuclear magnetic resonanceâ€“based study. Surgery, 2012, 152, 1118-1124.	1.0	44
157	A proteomic profile of washing fluid from the colorectal tract to search for potential biomarkers of colon cancer. Molecular BioSystems, 2012, 8, 1088.	2.9	19
158	Proteomic approach used in the diagnosis of Riedel's thyroiditis: a case report. Journal of Medical Case Reports, 2012, 6, 103.	0.4	2
159	Minimally invasive video-assisted thyroidectomy: an analysis of results and a revision of indications. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 818-822.	1.3	57
160	Genetic markers to discriminate benign and malignant thyroid nodules with undetermined cytology in an area of borderline iodine deficiency. Journal of Endocrinological Investigation, 2012, 35, 754-9.	1.8	5
161	High-intensity focused ultrasound as an alternative to the surgical approach in primary hyperparathyroidism: A preliminary experience. Journal of Endocrinological Investigation, 2011, 34, 655-659.	1.8	19
162	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. Pharmacological Research, 2011, 63, 59-67.	3.1	34

#	Article	IF	Citations
163	A proteomic approach to study parathyroid glands. Molecular BioSystems, 2011, 7, 687-699.	2.9	24
164	RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clinical Endocrinology, 2011, 74, 241-247.	1.2	101
165	Evaluation of formalin-fixed paraffin-embedded tissues in the proteomic analysis of parathyroid glands. Proteome Science, 2011, 9, 29.	0.7	25
166	Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome. Hormone and Metabolic Research, 2011, 43, e1-e1.	0.7	0
167	TWIST1 Plays a Pleiotropic Role in Determining the Anaplastic Thyroid Cancer Phenotype. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E772-E781.	1.8	39
168	Is Elastography Actually Useful in the Presurgical Selection of Thyroid Nodules with Indeterminate Cytology?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1826-E1830.	1.8	113
169	Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters. Thyroid, 2011, 21, 1209-1215.	2.4	39
170	Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with l-thyroxine. Endocrine-Related Cancer, 2011, 18, 429-437.	1.6	138
171	Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome. Hormone and Metabolic Research, 2011, 43, 126-129.	0.7	0
172	Diagnosis and treatment of autoimmune hypophysitis: a short review. Journal of Endocrinological Investigation, 2011, 34, e245-52.	1.8	24
173	Mast cells have a protumorigenic role in human thyroid cancer. Oncogene, 2010, 29, 6203-6215.	2.6	190
174	L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27â€Š914 patients. Endocrine-Related Cancer, 2010, 17, 231-239.	1.6	63
175	Correlation between theBRAFV600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4197-4205.	1.8	162
176	Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer. Endocrine-Related Cancer, 2010, 17, 785-796.	1.6	34
177	Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. European Journal of Endocrinology, 2010, 162, 763-770.	1.9	122
178	BRAFStatus of Follicular Variant of Papillary Thyroid Carcinoma and its Relationship to Its Clinical and Cytological Features. Thyroid, 2010, 20, 1263-1270.	2.4	31
179	Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1516-1527.	1.8	203
180	Real-Time Elastosonography: Useful Tool for Refining the Presurgical Diagnosis in Thyroid Nodules with Indeterminate or Nondiagnostic Cytology. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5274-5280.	1.8	177

#	Article	IF	Citations
181	CXC Chemokine Receptor 4 Immunodetection in the Follicular Variant of Papillary Thyroid Carcinoma: Comparison to Galectin-3 and Hector Battifora Mesothelial Cell-1. Thyroid, 2010, 20, 495-504.	2.4	24
182	Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica, 2010, 102, 405-8.	1.3	126
183	Dysregulation of secretion of CXC Î±-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-Î³ agonists. Endocrine-Related Cancer, 2009, 16, 1299-1311.	1.6	66
184	Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocrine-Related Cancer, 2009, 16, 1251-1260.	1.6	192
185	Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatmentâ˜†. European Journal of Cardio-thoracic Surgery, 2009, 35, 812-816.	0.6	61
186	A Ganglioneuroma with Features of a Thyroid Nodule: Intense Pain on Fine Needle Biopsy as a Diagnostic Clue. Thyroid, 2009, 19, 201-204.	2.4	7
187	The Î²-Catenin Axis Integrates Multiple Signals Downstream from RET/Papillary Thyroid Carcinoma Leading to Cell Proliferation. Cancer Research, 2009, 69, 1867-1876.	0.4	82
188	Management of pleural recurrence after curative resection of thymoma. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 1185-1189.	0.4	79
189	Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clinical Endocrinology, 2009, 70, 946-953.	1.2	63
190	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 715-721.	2.9	509
191	Contrast-enhanced ultrasonography in nodular splenomegaly associated with type B Niemannâ€“Pick disease: an atypical hemangioma enhancement pattern. Journal of Ultrasound, 2009, 12, 85-92.	0.7	9
192	Papillary thyroid cancer: Pathological parameters as prognostic factors in different classes of age. Otolaryngology - Head and Neck Surgery, 2008, 138, 200-203.	1.1	51
193	Fine-Needle Aspiration of Thyroid Nodules: Proteomic Analysis To Identify Cancer Biomarkers. Journal of Proteome Research, 2008, 7, 4079-4088.	1.8	99
194	Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. European Journal of Endocrinology, 2008, 159, 283-291.	1.9	55
195	Functional Characterization of the Novel T599I-VKSRdel BRAF Mutation in a Follicular Variant Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4398-4402.	1.8	32
196	Surgical treatment of pleural recurrence from thymoma. European Journal of Cardio-thoracic Surgery, 2008, 33, 707-711.	0.6	30
197	Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 682-687.	1.8	478
198	Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 591-596.	1.8	74

#	Article	IF	Citations
199	BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 511-520.	1.6	139
200	BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3943-3949.	1.8	482
201	A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma. Cancer Research, 2007, 67, 10148-10158.	0.4	167
202	RETGenetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4725-4729.	1.8	236
203	WWOX Expression in Different Histologic Types and Subtypes of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 884-891.	3.2	58
204	Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer. Cancer Research, 2007, 67, 11821-11829.	0.4	100
205	Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocrine-Related Cancer, 2007, 14, 1099-1105.	1.6	48
206	Role of frozen section associated with intraoperative cytology in comparison to FNA and FS alone in the management of thyroid nodules. European Journal of Surgical Oncology, 2007, 33, 769-775.	0.5	43
207	Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Human Pathology, 2007, 38, 1482-1488.	1.1	18
208	Lymphocyte and Immature Dendritic Cell Infiltrates in Differentiated, Poorly Differentiated, and Undifferentiated Thyroid Carcinoma. Thyroid, 2007, 17, 389-393.	2.4	77
209	Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. Thyroid, 2007, 17, 381-388.	2.4	64
210	Proteomic analysis of human thyroid fine needle aspiration fluid. Journal of Endocrinological Investigation, 2007, 30, 865-869.	1.8	14
211	The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3511-3516.	1.8	93
212	Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4085-4090.	1.8	370
213	Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy. Clinical Endocrinology, 2007, 67, 363-369.	1.2	55
214	Intrathyroidal Differentiated Thyroid Carcinoma: Tumor Size-Based Surgical Concepts. World Journal of Surgery, 2007, 31, 888-894.	0.8	40
215	Telomerase activity and hTERT mRNA expression in glial tumors. International Journal of Oncology, 2006, 28, 1555-60.	1.4	38
216	Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up. Journal of Thoracic Oncology, 2006, 1, 308-313.	0.5	35

#	Article	IF	Citations
217	INCIDENTAL THYROID CARCINOMA IN A LARGE SERIES OF CONSECUTIVE PATIENTS OPERATED ON FOR BENIGN THYROID DISEASE. ANZ Journal of Surgery, 2006, 76, 123-126.	0.3	109
218	Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clinical Endocrinology, 2006, 66, 061109020454002-???.	1.2	107
219	Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 546-553.	1.4	14
220	Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2389-2395.	1.8	41
221	Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up. Journal of Thoracic Oncology, 2006, 1, 308-313.	0.5	60
222	Thymomas: clinical-pathological correlations. Journal of Cardiovascular Surgery, 2006, 47, 89-93.	0.3	6
223	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	231
224	Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. British Journal of Cancer, 2005, 93, 453-457.	2.9	69
225	Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. BMC Microbiology, 2005, 5, 20.	1.3	30
226	Osteopontin Expression and Prognostic Significance in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6459-6465.	3.2	98
227	Type I Interferons Modulate the Expression of Thyroid Peroxidase, Sodium/Iodide Symporter, and Thyroglobulin Genes in Primary Human Thyrocyte Cultures. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1156-1162.	1.8	53
228	Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4703-4709.	1.8	38
229	All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor Î² Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2403-2411.	1.8	41
230	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5270-5278.	1.8	71
231	Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. British Journal of Cancer, 2005, 92, 681-689.	2.9	30
232	Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. European Journal of Cancer, 2005, 41, 2828-2835.	1.3	45
233	Advanced Stage Thymomas and Thymic Carcinomas: Results of Multimodality Treatments. Annals of Thoracic Surgery, 2005, 79, 1840-1844.	0.7	133
234	Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. Lung Cancer, 2005, 50, 309-317.	0.9	31

#	Article	IF	Citations
235	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	126
236	Immunohistochemical and Molecular Study of Radiation-Induced Multiple Meningiomas with Pleural and Pulmonary Metastasis. Tumori, 2004, 90, 328-332.	0.6	4
237	Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5175-5180.	1.8	252
238	Medullary and Papillary Tumors Are Frequently Associated in the Same Thyroid Gland without Evidence of Reciprocal Influence in Their Biologic Behavior. Thyroid, 2004, 14, 946-952.	2.4	60
239	Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. Journal of Endocrinology, 2004, 182, 479-484.	1.2	17
240	Expression and Mutational Status of c-kit in Small-Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4101-4108.	3.2	87
241	Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumors. European Journal of Endocrinology, 2004, 151, 215-222.	1.9	6
242	Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 163-168.	1.8	464
243	Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene, 2004, 23, 2188-2196.	2.6	43
244	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene, 2004, 23, 5958-5967.	2.6	119
245	Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathology and Applied Neurobiology, 2004, 30, 118-125.	1.8	81
246	Plasma and tissue chromogranin in patients with adrenocortical adenomas. Journal of Endocrinological Investigation, 2004, 27, 821-825.	1.8	7
247	Applications of tissue microarray technology in immunohistochemistry: A study on c-kit expression in small cell lung cancer. Human Pathology, 2004, 35, 1347-1352.	1.1	11
248	Identification of a Novel Point Mutation in the RET Gene (Ala883Thr), Which Is Associated with Medullary Thyroid Carcinoma Phenotype Only in Homozygous Condition. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5823-5827.	1.8	63
249	Mutations of Fas (APO-1/CD95) and p53 Genes in Nonmelanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery, 2003, 7, 112-118.	0.6	4
250	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	1.8	950
251	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens. Thyroid, 2003, 13, 765-770.	2.4	51
252	Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2). Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1897-1902.	1.8	115

#	Article	IF	Citations
253	Prevalence of Cancer in Follicular Thyroid Nodules: Is There Still a Role for Intraoperative Frozen Section Analysis?. Thyroid, 2003, 13, 389-394.	2.4	25
254	Telomerase in intracranial meningiomas. International Journal of Molecular Medicine, 2003, 12, 943-7.	1.8	20
255	Evaluation of telomerase in non-melanoma skin cancer. International Journal of Molecular Medicine, 2003, 11, 607-11.	1.8	18
256	Simian Virus 40-Like Sequences from Early and Late Regions in Human Thyroid Tumors of Different Histotypes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 892-899.	1.8	29
257	Mutations of Fas (APO-1/CD95) and p53 Genes in Nonmelanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery, 2003, 7, 112-118.	0.6	10
258	A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. British Journal of Cancer, 2002, 86, 558-563.	2.9	123
259	DNA Immunization of Mice against the VP1 Capsid Protein of Coxsackievirus B4. Scandinavian Journal of Immunology, 2002, 56, 448-455.	1.3	11
260	Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4160-4165.	1.8	90
261	Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. International Journal of Oncology, 2002, 20, 155-9.	1.4	10
262	Evaluation of telomerase mRNA (hTERT) in colon cancer. International Journal of Oncology, 2002, 21, 493-7.	1.4	11
263	Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. Journal of Endocrinological Investigation, 2002, 25, 176-180.	1.8	46
264	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. American Journal of Pathology, 2002, 160, 247-254.	1.9	103
265	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying theRET/PTC1 rearrangement. International Journal of Cancer, 2002, 97, 608-614.	2.3	41
266	Evaluation of telomerase in the development and progression of colon cancer. International Journal of Molecular Medicine, 2002, 10, 589-92.	1.8	28
267	Thymic carcinoma: a report of 13 cases. European Journal of Surgical Oncology, 2001, 27, 636-640.	0.5	31
268	Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene, 2001, 20, 6632-6637.	2.6	22
269	The multimodality treatment of thymic carcinoma. European Journal of Cardio-thoracic Surgery, 2001, 19, 566-569.	0.6	65
270	RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. European Journal of Endocrinology, 2001, 145, 599-604.	1.9	50

#	Article	IF	Citations
271	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3211-3216.	1.8	234
272	Contralateral Papillary Thyroid Cancer is Frequent at Completion Thyroidectomy with No Difference in Low- and High-Risk Patients. Thyroid, 2001, 11, 877-881.	2.4	140
273	New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. Clinical Endocrinology, 2000, 53, 131-136.	1.2	17
274	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. Laboratory Investigation, 2000, 80, 1413-1419.	1.7	26
275	N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression. Thyroid, 2000, 10, 19-23.	2.4	159
276	Surgical and Pathological Changes After Percutaneous Ethanol Injection Therapy of Thyroid Nodules. Thyroid, 2000, 10, 1087-1092.	2.4	28
277	Tumour necrosis factor- Î± and transforming growth factor- Î² are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. British Journal of Cancer, 2000, 83, 480-486.	2.9	46
278	Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis.. International Journal of Oncology, 2000, 16, 485-9.	1.4	5
279	Cyclin D1 Overexpression in Thyroid Carcinomas: Relation with Clinico-Pathological Parameters, Retinoblastoma Gene Product, and Ki67 Labeling Index. Thyroid, 2000, 10, 741-746.	2.4	50
280	RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenetic and Genome Research, 2000, 88, 56-61.	0.6	67
281	Modulation of neoangiogenesis in bronchial preneoplastic lesions.. Oncology Reports, 1999, 6, 813-7.	1.2	43
282	Quantitation by competitive PCR assay of vascular endothelial growth factor in non-small cell lung carcinomas.. International Journal of Oncology, 1999, 14, 161-8.	1.4	8
283	Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. British Journal of Cancer, 1999, 79, 363-369.	2.9	84
284	Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. British Journal of Cancer, 1999, 80, 579-584.	2.9	47
285	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of thebcl-2 gene. , 1999, 81, 956-962.		13
286	Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. Journal of Endocrinological Investigation, 1999, 22, 273-278.	1.8	27
287	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl2 gene. International Journal of Cancer, 1999, 81, 956-962.	2.3	1
288	Usefulness of Ultrafast Papanicolaou-stained scrape preparations in intraoperative management of thyroid lesions. Modern Pathology, 1999, 12, 653-7.	2.9	38

#	Article	IF	Citations
289	Simian virus 40-like DNA sequences in human papillary thyroid carcinomas. Oncogene, 1998, 16, 665-669.	2.6	50
290	bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. European Journal of Cancer, 1998, 34, 718-723.	1.3	95
291	Ectopic Expression of Bone Sialoprotein in Human Thyroid Cancer. Thyroid, 1998, 8, 637-641.	2.4	62
292	Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies. Clinical Cancer Research, 1998, 4, 381-7.	3.2	23
293	Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-11. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4094-4100.	1.8	38
294	Persistent Infection of Human Vascular Endothelial Cells by Group B Coxsackieviruses. Journal of Infectious Diseases, 1997, 175, 693-696.	1.9	57
295	In mammary epithelial cells p53-mediated apoptosis in response to DNA damage is dependent on the agent and can be influenced by growth factors. Endocrine-Related Cancer, 1997, 4, 55-66.	1.6	2
296	Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study. Journal of the National Cancer Institute, 1997, 89, 881-886.	3.0	273
297	Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. British Journal of Cancer, 1997, 75, 1295-1301.	2.9	118
298	Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. British Journal of Cancer, 1997, 75, 537-541.	2.9	89
299	Down-regulation of thenm23.h1 gene inhibits cell proliferation. , 1997, 73, 297-302.		49
300	c-Ha-ras transfection and expression of MDR-related genes in MCF-10A human breast cell line. Anticancer Research, 1997, 17, 3587-92.	0.5	9
301	Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS) Tj ETQq1 1 0.784314 rgBT /Overlock	3.2	75
302	Neoangiogenesis: A putative marker of malignancy in non-small-cell-lung-cancer (NSCLC) development. , 1996, 67, 615-619.		32
303	Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. British Journal of Cancer, 1996, 73, 1356-1361.	2.9	14
304	bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. British Journal of Cancer, 1996, 73, 139-143.	2.9	85
305	Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2006-2009.	1.8	127
306	Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Molecular Pharmacology, 1996, 49, 972-9.	1.0	25

#	Article	IF	Citations
307	Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Research, 1996, 56, 3118-22.	0.4	42
308	Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study. Clinical Cancer Research, 1996, 2, 1777-80.	3.2	19
309	Productive HIV-1 infection of normal human mammary epithelial cells. Aids, 1995, 9, 859-866.	1.0	77
310	Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1Î² plus tumor necrosis factor-Î±. Journal of Medical Virology, 1995, 47, 355-363.	2.5	52
311	NM23 gene expression correlates with cell growth rate and S-phase. International Journal of Cancer, 1995, 60, 837-842.	2.3	66
312	Invasive phenotype of MCF10A cells overexpressing câ€Haâ€•ras and câ€•erb Bâ€2 oncogenes. International Journal of Cancer, 1995, 63, 815-822.	2.3	76
313	Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. Journal of Pathology, 1995, 177, 57-63.	2.1	166
314	Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. British Journal of Cancer, 1995, 71, 1003-1007.	2.9	185
315	p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin.. Journal of Cell Biology, 1995, 128, 1185-1196.	2.3	162
316	Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. European Journal of Cancer, 1995, 31, 178-183.	1.3	113
317	Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery, 1995, 118, 1031-1035.	1.0	80
318	THE EFFECT OF FGF-3 INT-2 ON GROWTH AND TRANSFORMATION OF MCF-10A NORMAL HUMAN MAMMARY EPITHELIAL-CELLS IS DISTINCT FROM FGF-1 AND FGF-2. International Journal of Oncology, 1994, 4, 1365-70.	1.4	0
319	EFFECTS OF MUTANT P53 GENES ON TRANSFORMATION OF HUMAN MAMMARY EPITHELIAL-CELLS. International Journal of Oncology, 1994, 4, 1077.	1.4	2
320	LEVELS OF P53 ANTIGEN IN THE SERUM OF NONSMALL CELL LUNG-CANCER PATIENTS CORRELATE WITH POSITIVE P53 IMMUNOHISTOCHEMISTRY ON TUMOR SECTIONS, TUMOR NECROSIS AND NODAL INVOLVEMENT. International Journal of Oncology, 1994, 5, 553-8.	1.4	8
321	Human non-small cell lung cancer: P53 protein accumulation is an early event and persists during metastatic progression. Journal of Pathology, 1994, 174, 23-31.	2.1	51
322	Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor Î²1 (TGF-Î²1): Lack of growth-inhibitory effect on cells expressing the simian virus 40 large-t antigen. International Journal of Cancer, 1994, 56, 736-742.	2.3	25
323	Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line withc-Ha-ras andc-erbB-2 oncogenes. International Journal of Cancer, 1994, 59, 208-211.	2.3	20
324	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. European Journal of Cancer, 1994, 30, 171-174.	1.3	37

#	Article	IF	Citations
325	Treatment of preclinical medullary thyroid carcinoma in MEN 2A gene carrier. Lancet, The, 1994, 344, 1084-1085.	6.3	8
326	ANAPLASTIC THYROID-CARCINOMA - A RETROSPECTIVE CLINICAL AND IMMUNOHISTOCHEMICAL STUDY. Oncology Reports, 1994, 1, 921-5.	1.2	6
327	Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene, 1994, 9, 291-8.	2.6	46
328	Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: Defective il6 expression in mammary carcinoma. International Journal of Cancer, 1993, 55, 926-930.	2.3	86
329	Production of Cytokines and Response to Them in Normal and Transformed Human Mammary Epithelial Cells. Annals of the New York Academy of Sciences, 1993, 698, 126-130.	1.8	6
330	MARKERS OF CELL-PROLIFERATION AS PROGNOSTIC FACTORS IN DIFFERENTIATED THYROID-CANCER. International Journal of Oncology, 1993, 3, 1077-81.	1.4	0
331	Growth-stimulating activity of interleukin 6 on human mammary epithelial cells transfected with the int-2 gene. Cancer Research, 1993, 53, 2957-60.	0.4	15
332	Expression of calcitonin gene-related peptide in medullary thyroid cancer. Journal of Endocrinological Investigation, 1992, 15, 539-542.	1.8	10
333	Regulation of surface-differentiation molecules by epidermal growth factor, transforming growth factor alpha, and hydrocortisone in human mammary epithelial cells transformed by an activatedc-Ha-ras proto-oncogene. International Journal of Cancer, 1992, 51, 634-640.	2.3	21
334	Interferon-Î±/Î² in virus-induced mouse mammary carcinogenesis: Effects on the spontaneous process and on the progression of transplanted pre-neoplastic lesions. International Journal of Cancer, 1992, 51, 956-961.	2.3	1
335	Matrigel promotes retinoblastoma cell growthin vitro andin vivo. International Journal of Cancer, 1992, 52, 234-240.	2.3	46
336	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-Î± genes on in vitro transformation of human mammary epithelial cells. Molecular Carcinogenesis, 1992, 6, 43-52.	1.3	65
337	Mutated c-Ha-ras oncogene alters cytokeratin expression in the human breast epithelial cell line MCF-10A. American Journal of Pathology, 1992, 140, 1483-8.	1.9	7
338	Cell surface glycosylation changes accompanying immortalization and transformation of normal human mammary epithelial cells. Cancer Letters, 1991, 57, 27-36.	3.2	14
339	Adjuvant Chemotherapy for T1-2N0M0 Small Cell Lung Cancer: Single-Agent or Combination Chemotherapy?. Cancer Investigation, 1991, 9, 19-25.	0.6	1
340	Medullary Thyroid Cancer: An Immunohistochemical and Humoral Study Using Six Separate Antigens. American Journal of Clinical Pathology, 1991, 95, 300-308.	0.4	82
341	Surgery Plus Adjuvant Chemotherapy for T1â€“3N0M0 Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1991, 14, 218-224.	0.6	37
342	Transformation of Human Breast Epithelial Cells by c-Ha-ras Oncogene. Molecular Carcinogenesis, 1991, 4, 25-35.	1.3	155

#	Article	IF	Citations
343	Increased invasive, chemotactic and locomotive abilities of c-Ha-ras-transformed human breast epithelial cells. Invasion & Metastasis, 1991, 11, 38-47.	0.5	25
344	Fr-MLV infection induces erythroleukaemia instead of lymphoid leukaemia in mice given pituitary grafts. British Journal of Cancer, 1990, 61, 841-845.	2.9	5
345	Transfection of Human Breast Epithelial Cells with Foreign Dna Using Different Transfecting Techniques. Tumori, 1990, 76, 455-460.	0.6	3
346	Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1990, 1, 407-20.	0.8	27
347	Transfection of human breast epithelial cells with foreign DNA using different transfecting techniques. Tumori, 1990, 76, 455-60.	0.6	1
348	A human monoclonal autoantibody isolated from a patient with infectious mononucleosis reactive with both self antigens and Epstein-Barr virus nuclear antigen (EBNA). Immunology Letters, 1989, 22, 211-216.	1.1	6
349	Somatostatin in medullary thyroid cancer.In vitro andin vivo studies. Cancer, 1989, 63, 1189-1195.	2.0	46
350	Influence of T and N stages on long-term survival in resectable small cell lung cancer. European Journal of Surgical Oncology, 1989, 15, 337-40.	0.5	17
351	Optimal treatment for T1-3NOMO small cell lung cancer: surgery plus adjuvant chemotherapy. Anticancer Research, 1989, 9, 1623-5.	0.5	6
352	Osteosarcoma of the Myometrium Synchronous with Bilateral Papillary Cystadenocarcinoma of the Ovary and Papillary Adenocarcinoma of the Cervix. Tumori, 1988, 74, 227-231.	0.6	6
353	Differences in progression of BALB/cfRIII and BALB/cfC3H mammary hyperplastic alveolar nodules transplanted into the gland-free fat pads of BALB/c mice. Cancer Research, 1988, 48, 3197-202.	0.4	4
354	Osteosarcoma of the myometrium synchronous with bilateral papillary cystadenocarcinoma of the ovary and papillary adenocarcinoma of the cervix. Tumori, 1988, 74, 227-31.	0.6	2
355	Endosonographic staging of rectal carcinoma. Gastrointestinal Radiology, 1987, 12, 289-295.	0.4	38
356	Lung colonization and metastasis of murine mammary tumors: relationship to various characteristics of the primary tumors. Invasion & Metastasis, 1987, 7, 275-83.	0.5	3
357	Early Pathologic Changes in Experimental and Human Breast Cancer: Facts and Comments. Annals of the New York Academy of Sciences, 1986, 464, 231-261.	1.8	7
358	Reciprocal interference between milk-transmitted mammary tumor virus and Friend leukemia viruses in mice: possible role of the interferon system. Cancer Research, 1986, 46, 4064-70.	0.4	3
359	Systemic Lymphoid Atrophy in Coxsackievirus B3-Infected Mice: Effects of Virus and Immunopotentiating Agents. Journal of Infectious Diseases, 1985, 151, 1100-1108.	1.9	35
360	Lobuloalveolar differentiation and tumorigenesis: two separate activities of mouse mammary tumor virus. Cancer Research, 1983, 43, 5879-82.	0.4	19

#	Article	IF	Citations
361	Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncology Reports, 0, , .	1.2	7
362	Tumour necrosis factor-Î±: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. International Journal of Molecular Medicine, 0, , .	1.8	2
363	Genetic heterogeneity of medullary thyroid carcinoma. Endocrine Abstracts, 0, , .	0.0	0